iMDx (NASDAQ:IMDX) announced positive results from a head-to-head study comparing its GraftAssureIQ digital PCR-based test kit with NGS-based technology for kidney transplant rejection testing. The …
Tag:
IMDX
-
-
The study shows consistent results for IMDX's digital PCR-based test kits using IMDX's flagship technology and commercially available DD-CFDNA test kits and NGS kits, as well as 96 implant patients. …